Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2022 09:30 ET | Source: Market Research Future

Neurorehabilitation Devices Market Size to Hit USD 2.33 Billion by 2030 at 7.9% CAGR – Report by Market Research Future (MRFR)

New York, USA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Neurorehabilitation Devices Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Neurorehabilitation...
December 02, 2022 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer...
December 02, 2022 08:00 ET | Source: EQRx, Inc.

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

Submission is EQRx’s first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated...
December 02, 2022 06:30 ET | Source: Beam Therapeutics

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
December 02, 2022 06:00 ET | Source: Bionomics Ltd

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
December 02, 2022 05:30 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Biological Safety Cabinets Market worth $0.4 billion by 2027 - Exclusive Report by MarketsandMarkets™

Chicago, Dec. 02, 2022 (GLOBE NEWSWIRE) -- According to the new market research report published by MarketsandMarkets, "Biological Safety Cabinet Market by Type (Class I, Class II (Type A, Type B),...
December 02, 2022 02:19 ET | Source: Allied Market Research

Global Tumor Ablation Market to Garner $4.7 Billion by 2031: Allied Market Research

Portland, OR, Dec. 02, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Tumor Ablation Market was accounted for $1.3 billion in 2021, and is...
December 01, 2022 17:34 ET | Source: Y-mAbs Therapeutics, Inc

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
December 01, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
December 01, 2022 16:01 ET | Source: ObsEva SA

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical...